Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability

Derivation of Primary Donor Cell Lines for Human Cell Reprogramming

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00628199

Enrollment

Registered

2008-03-04

Start date

2007-09-30

Completion date

2030-01-31

Last updated

2022-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Metabolic Diseases

Brief summary

This is a research study in which your cells will be used for somatic cell nuclear transfer (SCNT), and/or genetic reprogramming research which may result in the production of stem cell lines. This study does not provide treatment.

Detailed description

It is thought that studies of genetic reprogramming and SCNT using human cells have the potential to give us new basic knowledge about human development. Current work will focus on developing this basic knowledge. In the future, human embryonic stem cell lines (hESC) derived from genetic reprogramming and SCNT may also have the potential to develop into cell types that are useful for cell-based therapies to treat human disease and disability.

Interventions

PROCEDUREImproving the scientific process of human cell reprogramming

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

1. Donors with a degenerative disease phenotype or genetic disorders such as Type I Diabetes, heart disease, or infertility (azoospermia and premature ovarian failure)

Exclusion criteria

1. Unable to read or understand English. 2. Unable to provide skin biopsy sample due to skin condition in the underarm area.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026